MAP2K4、SUMO-1、BRCA1在年轻子宫内膜癌患者中的表达分析

目的探讨丝裂原活化蛋白激酶4(MAP 2K4)、小类泛素化修饰蛋白1(SUMO-1)、乳腺癌易感基因1(BRCA1)在年轻子宫内膜癌患者中表达变化。方法选取2005年11月至2014年3月复旦大学附属妇产科医院80例年轻子宫内膜癌(EC)患者为EC组,80例子宫内膜非典型增生患者为非典型增生组、80例子宫内膜正常患者为正常组。对比3组患者组织中MAP2K4、SUMO-1、BRCA1表达,分析MAP2K4、SUMO-1、BRCA1表达与EC组患者临床病理参数、5年生存率关系。结果 EC组子宫内膜组织中MAP2K4、BRCA1表达低于非典型增生组、正常组,SUMO-1表达高于非典型增生组、正常组(χ^2值分别为64.73、60.67、64.52,均P <0.05);临床分期为Ⅲ~Ⅳ期、组织分化程度为中低分化、肌层浸润深度≥1/2、有淋巴结转移的EC组患者MAP2K4、BRCA1表达低于临床分期为Ⅰ~Ⅱ期、组织分化程度为高分化、肌层浸润深度<1/2、无淋巴结转移患者,SUMO-1表达高于临床分期为Ⅰ~Ⅱ期、组织分化程度为高分化、肌层浸润深度<1/2、无淋巴结转移患者(χ^2值分别为6.67、4.98、4.98、7.87、5.22、6.88、5.79、6.26、4.51、5.13、7.13、5.94,均P <0.05);MAP2K4、BRCA1在EC组织中阳性表达者5年生存率高于阴性表达者,SUMO-1阳性表达者5年生存率低于阴性表达者(χ^2值分别为5.79、4.39、6.35,均P <0.05)。结论 MAP2K4、BRCA1在年轻EC患者中呈低表达,SUMO-1呈高表达,且其表达与患者临床病理参数及生存率密切相关。

Expression analysis of MAP2K4, SUMO-1 and BRCA1 gene in young endometrial cancer patients

Objective To investigate the expression of mitogen-activated protein kinase 4(MAP2 K4), small ubiquitin-modified protein 1(SUMO-1) and breast cancer susceptibility gene 1(BRCA1) in young endometrial cancer(EC) patients. Methods A total of 80 young patients with EC admitted to Affiliated Obstetrics and Gynecology Hospital of Fudan University from November 2005 to March 2014 were enrolled in the EC group. At the same time, 80 cases of patients with endometrial atypical hyperplasia were enrolled in the atypical hyperplasia group and 80 women with normal endometrium were enrolled in the normal group. The expressions of MAP2 K4, SUMO-1 and BRCA1 in the endometrial tissues among the three groups were compared, and then the associations between the expressions of MAP2 K4, SUMO-1, BRCA1 and clinical pathological parameters, 5-year survival rate of the EC group were analyzed. Results The expressions of MAP2 K4 and BRCA1 in the endometrium of EC group were lower than those of atypical hyperplasia group and normal group(χ~2 values were 64.730 and 60.672, respectively, both P<0.05), while the expression of SUMO-1 in EC group was higher than that in the atypical hyperplasia group and normal group(χ~2 = 64.518, P<0.05). In addition, in EC group, the expression levels of MAP2 K4 and BRCA1 in patients with III ~ IV clinical stage, moderate and poor tissue differentiation, ≥ 1/2 myometrial invasion depth and lymph node metastasis were lower than those in patients with I ~ II clinical stage, high tissue differentiation, ≥ 1/2 myometrial invasion depth and no lymph node metastasis(χ~2 values were 6.67, 4.98, 4.98, 7.87, 5.22, 6.88, 5.79 and 6.26, respectively, all P<0.05). And in EC group, the expression level of SUMO-1 in patients with III ~ IV clinical stage, moderate and poor tissue differentiation, ≥ 1/2 myometrial invasion depth and lymph node metastasis were lower than those in patients with I ~ II clinical stage, high tissue differentiation,<1/2 myometrial invasion depth and no lymph node metastasis(χ~2 values were 4.51, 5.13, 7.13 and 5.94, respectively, all P<0.05). The 5-year prognosis survival rates in patients with MAP2 K4 and BRCA1 positive expression in EC tissues were significantly higher than those with negative expression, while the 5-year prognosis survival rate in patients with SUMO-1 positive expression was significantly lower than that with negative expression(χ~2 values were 5.79, 4.39 and 6.35, respectively, all P<0.05). Conclusion MAP2 K4 and BRCA1 gene are low expression in young EC patients, while SUMO-1 is highly expressed, and the expression of these three genes is closely related to pathological parameters and the prognosis survival rate for patients with EC.